Background -A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. To investigate the mechanism of action of auranofin the bronchial responsiveness to inhaled methacholine has been studied in well controlled asthmatic subjects. Methods -Nineteen adult asymptomatic asthmatic subjects received auranofin (3 mg orally twice a day) or inactive placebo in random order for 12 weeks in a double blind fashion. Bronchial responsiveness to inhaled methacholine and pulmonary function tests were measured at the same time on different days before, and six and 12 weeks after, each treatment.
Results -Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin was decreased compared with that before treatment with auranofin and 12 weeks after treatment with inactive placebo, although the treatment did not improve pulmonary function tests.
Conclusions -Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin is decreased in a group of mild asymptomatic asthmatic patients with normal lung function. (Thorax 1994; 49:649-65 1) matic patients in a double blind, placebo controlled fashion.
Methods

PATIENTS
Twenty five asymptomatic outpatients with bronchial asthma were recruited from our asthma clinic. Patients who had received systemic steroid treatment were excluded from the study. All other routinely used agents were continued for 12 weeks before and during the period of the study. Of 15 patients receiving beclomethasone dipropionate 13 had taken it for more than one year and two for more than six months. None had experienced an exacerbation of asthma or respiratory tract infection for 12 weeks before the study. The study was approved by the ethics committee of the Tohoku University School of Medicine and all patients gave written informed consent.
STUDY DESIGN
Auranofin or placebo, in 3 mg tablet form, was administered orally twice a day for 12 weeks in a double blind fashion. Blood sampling and measurements of bronchial responsiveness to methacholine and pulmonary function tests were carried out at the same time on different days before, and six and 12 weeks after, each treatment. All subjects were required to record clinical symptoms and concomitant medication during the study period. Bronchial responsiveness to inhaled methacholine was measured by the astograph method.5 To evaluate response curves of total respiratory resistance (Rrs) three indices were defined as follows: (1) Rrs-cont: mean values of respiratory resistance during inhalation of saline; (2) Dmin: cumulative units of methacholine from the start of the study to the beginning of an increase in respiratory resistance; and (3) PD35-Grs: cumulative units of methacholine from the start of the study to the point at which total respiratory conductance decreased 35% from its baseline value. One unit represents one minute of inhalation of 1 mg/ml methacholine.
FEV, and FVC were measured with a spirometer (OST-80A; CHEST, Tokyo) and the best of three satisfactory measurements was recorded.
MEASUREMENT OF SERUM GOLD CONCENTRATION Five ml of blood was collected in a heparinised container before, and six and 12 weeks after, the start of treatment. Gold concentrations in the blood were measured by atomic absorption analysis spectrophotometry after the study had been completed.
STATISTICAL ANALYSIS
Twenty four patients, excluding one who was found to be suffering from a duodenal ulcer one week after the treatment, completed the study. Before unblinding the data all subjects were reviewed and five were excluded because of respiratory tract infection (two), a more than 25% change in Rrs-cont (two), and poor compliance (one).
Logarithmic transformation of Dmin and PD35-Grs was used for statistical analysis. Results were expressed as mean (SD). Results from the auranofin and placebo groups were compared by the unpaired Student's t test and those within each group were compared by the paired Student's t test.
Results
Efficacy data were analysed for the 19 subjects who completed the study. Nine patients received auranofin and 10 received an inactive placebo. Mean (SD) age in the auranofin group was 46 2 (12 7) years and mean (SD) baseline FEV, was 104.3% (20 4% ) of predicted. In the placebo group the mean age was 40 0 (13 9) years and mean baseline FEVI was 10177% (17 5%) of predicted. Eleven patients (five in the auranofin group and six in the placebo group) were receiving an inhaled steroid. Thus, there were no significant differences in age, baseline FEVI, or concomitant medications between the two groups. As shown in the figure there was a significant improvement in Dmin (p <005) and PD35-Grs (p<0005) 12 weeks after auranofin treatment compared with 12 weeks after placebo treatment, although no significant differences in Dmin or PD35-Grs were found 0 and six weeks after treatments between the groups. In the auranofin group there was an improvement in Dmin (p<0005) and PD35-Grs (p < 005) 12 weeks after the treatment compared with baseline. Treatment with auranofin for 12 weeks therefore significantly decreased non-specific bronchial responsiveness. In addition, after 12 The mean (SD) blood concentrations of gold were 0 003 (0 001), 0 460 (0-114), and 0 483 (0 100) pg/ml 0, six, and 12 weeks after the treatment, respectively. The concentrations after six and 12 weeks of treatment were therefore significantly higher than those after 0 weeks, although there was no significant difference in the concentration between six and 12 weeks. In the placebo group no increase in the blood concentration of gold was found in any of the subjects. 
